首页> 外文期刊>Future Virology >Efficacy of prokaryotic and eukaryotic recombinant fusion proteins (M2e-carliticulin) as an influenza universal vaccine in mice C57Bl/6
【24h】

Efficacy of prokaryotic and eukaryotic recombinant fusion proteins (M2e-carliticulin) as an influenza universal vaccine in mice C57Bl/6

机译:原核和真核重组融合蛋白(M2E-Carliticulin)作为小鼠C57BL / 6的流感疫苗的疗效

获取原文
获取原文并翻译 | 示例
           

摘要

Aim: The aim of this work was a preliminary study on the immunogenicity and protectivity effect of eukaryotic and prokaryotic expressed M2e-Carliticulin (CRT) in the experimental mice. Materials & methods: We constructed and expressed M2e-CRT in Escherichia coli and Pichia pastoris. Then we evaluated the immunological responses and virus challenge following injection of M2e-CRT fusion protein, expressed in E. coli and P. pastoris as a recombinant protein vaccine. According to this issue, a prime-boost administration of M2e-CRT by subcutaneous route in C57Bl/6 mouse model was done. Results: Both fusion proteins induced comparable immunologic responses. Conclusion: But because of easier and cheaper purification in prokaryote system this has led to the M2e-CRT as a vaccine candidate in prokaryote system compared with eukaryotic is preferred.
机译:目的:这项工作的目的是对实验小鼠在实验小鼠中真核和原核表达的M2E-Carliticulin(CRT)的免疫原性和保护作用的初步研究。 材料& 方法:我们在大肠杆菌和Pichia Pastoris中构建并表达了M2E-CRT。 然后,我们评估了注射M2E-CRT融合蛋白后的免疫应答和病毒攻击,以大肠杆菌和P. Pastoris表示为重组蛋白质疫苗。 根据该问题,完成了在C57BL / 6小鼠模型中通过皮下途径促进M2E-CRT的初始升压施用。 结果:两种融合蛋白均诱导可比免疫反应。 结论:但由于原核生系统中更容易和更便宜的净化,这使得与真核生物相比,将M2E-CRT作为原核生物系统中的疫苗候选者是优选的。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号